Comprehensive Therapy

, Volume 32, Issue 3, pp 158–162 | Cite as

Systemic lupus erythematosus Current state of diagnosis and treatment

Original Article
  • 9 Downloads

Abstract

Systemic lupus erythematosus is a chronic autoimmune condition with a wide spectrum of clinical manifestations, characterized by the production of auto-antibodies to components of the cell nucleus. Treatments include various immunosuppressive regimens, and newer biological therapies show promising results.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Petri M. Systemic lupus erythematosus. In: Clinical Primer of Rheumatology (Koopman WJ ed.) Lippincot Williams & Wilkins, Philadelphia. 2003, pp. 164–170.Google Scholar
  2. 2.
    Uramoto KM, Michet CJJ, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum 1999;42:46–50.PubMedCrossRefGoogle Scholar
  3. 3.
    Selmi C, Lleo A, Zuin M, et al. Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs 2006;7:451–456.PubMedGoogle Scholar
  4. 4.
    Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353(24):2550–2558.PubMedCrossRefGoogle Scholar
  5. 5.
    Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–1277.PubMedCrossRefGoogle Scholar
  6. 6.
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.PubMedCrossRefGoogle Scholar
  7. 7.
    Buyon J. Systemic lupus erythematosus. Clinical and laboratory features. In: Primer on the Rheumatic Diseases (Klippel JH ed.). Arthritis Foundation. Atlanta, 2001, pp. 335–346.Google Scholar
  8. 8.
    The Canadian Hydroxychoroquine Study Group. A randomized study effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324:150–154.CrossRefGoogle Scholar
  9. 9.
    Tseng C, Buyon J, Belmont HM, et al. Moderate dose steroids prevent severe flares of serologically active, clinically stable SLE patients. Arthritis Rheum 2003;48:S260.Google Scholar
  10. 10.
    Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121–2131.PubMedCrossRefGoogle Scholar
  11. 11.
    Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52:2761–2767.PubMedCrossRefGoogle Scholar
  12. 12.
    Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219–2228.PubMedCrossRefGoogle Scholar
  13. 13.
    Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971–980.PubMedCrossRefGoogle Scholar
  14. 14.
    Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580–2589.PubMedCrossRefGoogle Scholar
  15. 15.
    Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005;44:1542–1545.CrossRefGoogle Scholar
  16. 16.
    Burt RK, Traynor A, Statkute L, et al. Nomyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006;295:527–535.PubMedCrossRefGoogle Scholar
  17. 17.
    Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplant in systemic lupus erythematosus. Arthritis Rheum 2003;48:166–173.PubMedCrossRefGoogle Scholar
  18. 18.
    Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579–580.PubMedCrossRefGoogle Scholar
  19. 19.
    Furie R, Stohl W, Ginzler E, et al. Safety, pharmacokinetics and pharmacodynamic results of a phase I single and double dose-escalation study of lymphostat B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum 2003;48:S377.Google Scholar
  20. 20.
    Alarcon-Segovia D, Tumlin AJ, Furie R, et al.: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:442–454.PubMedCrossRefGoogle Scholar
  21. 21.
    Petri M, Mease PJ, Merrill JT, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum 2004;50:2858–2868.PubMedCrossRefGoogle Scholar
  22. 22.
    Mease PJ, Ginzler EM, Gluck OS, et al. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol 2005;32(4):616–621.PubMedGoogle Scholar

Copyright information

© ASCMS 2006

Authors and Affiliations

  1. 1.Rheumatology DepartmentLoma Linda UniversityLoma Linda

Personalised recommendations